AbCellera Biologics leverages a proprietary discovery platform generating partnership revenues primarily via milestones and royalties, but its financial history shows significant operating losses and fluctuating cash flows due to partner dependence and lost COVID-19 royalty streams. The company is advancing internal clinical trials with early-stage candidates, yet success hinges on milestones outside its direct control. Capital allocation focuses on sustaining technology infrastructure and pipeline development despite ongoing negative free cash flow and negative ROE characteristic of pipeline-stage biotech. Litigation settlements and regulatory risks compound the operational challenges while pipeline progress and partner developments remain key value drivers.